Loading...
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study
Djebbari, Faouzi Rampotas, Alexandros Vallance, Grant Panitsas, Fotios Basker, Nanda Sangha, Gina Salhan, Beena Karim, Farheen Al-Kaisi, Firas Gudger, Amy
Djebbari, Faouzi
Rampotas, Alexandros
Vallance, Grant
Panitsas, Fotios
Basker, Nanda
Sangha, Gina
Salhan, Beena
Karim, Farheen
Al-Kaisi, Firas
Gudger, Amy
Authors
Djebbari, Faouzi
Rampotas, Alexandros
Vallance, Grant
Panitsas, Fotios
Basker, Nanda
Sangha, Gina
Salhan, Beena
Karim, Farheen
Al-Kaisi, Firas
Gudger, Amy
Ngu, Loretta
Poynton, Matt
Lam, Ho Pui Jeff
Morgan, Lowri
Yang, Laura
Young, Jennifer
Walker, Mairi
Tsagkaraki, Ismini
Anderson, Laura
Chauhan, Saleena Rani
Maddams, Rebecca
Soutar, Richard
Triantafillou, Margarita
Prideaux, Steve
Obeidalla, Abubaker
Eyre, Toby A
Bygrave, Ceri
Basu, Supratik
Ramasamy, Karthik
Rampotas, Alexandros
Vallance, Grant
Panitsas, Fotios
Basker, Nanda
Sangha, Gina
Salhan, Beena
Karim, Farheen
Al-Kaisi, Firas
Gudger, Amy
Ngu, Loretta
Poynton, Matt
Lam, Ho Pui Jeff
Morgan, Lowri
Yang, Laura
Young, Jennifer
Walker, Mairi
Tsagkaraki, Ismini
Anderson, Laura
Chauhan, Saleena Rani
Maddams, Rebecca
Soutar, Richard
Triantafillou, Margarita
Prideaux, Steve
Obeidalla, Abubaker
Eyre, Toby A
Bygrave, Ceri
Basu, Supratik
Ramasamy, Karthik
Editors
Other contributors
Affiliation
Epub Date
Issue Date
2022-06-06
Submitted date
Subjects
Alternative
Abstract
Objectives There are no real-world data describing infection morbidity in relapsed/refractory myeloma (RRMM) patients treated with anti-CD38 isatuximab in combination with pomalidomide and dexamethasone (IsaPomDex). In this UK-wide retrospective study, we set out to evaluate infections experienced by routine care patients who received this novel therapy across 24 cancer centres during the COVID-19 pandemic. Methods The primary endpoint was infection morbidity (incidence, grading, hospitalization) as well as infection-related deaths. Secondary outcomes were clinical predictors of increased incidence of any grade (G2–5) and high grade (≥G3) infections. Results In a total cohort of 107 patients who received a median (IQR) of 4 cycles (2–8), 23.4% of patients experienced ≥1 any grade (G2–5) infections (total of 31 episodes) and 18.7% of patients experienced ≥1 high grade (≥G3) infections (total of 22 episodes). Median time (IQR) from start of therapy to first episode was 29 days (16–75). Six patients experienced COVID-19 infection, of whom 5 were not vaccinated and 1 was fully vaccinated. The cumulative duration of infection-related hospitalizations was 159 days. The multivariate (MVA) Poisson Regression analysis demonstrated that a higher co-morbidity burden with Charlson Co-morbidity Index (CCI) score ≥4 (incidence rate ratio (IRR) = 3, p = 0.012) and sub-optimal myeloma response less than a partial response (<PR) (p = 0.048) are independent predictors of ≥ G3 infections. Conclusion Our study described initial results of infection burden during IsaPomDex treatment. We recommend close monitoring particularly in elderly patients with co-morbidities, the effective use of an-infective prophylaxis, as well as optimal vaccination strategies, to limit infections.
Citation
Djebbari, F., Rampotas, A., Vallance, G. et al. (2022) Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study. Hematology, 27:1, 691-699, DOI: 10.1080/16078454.2022.2082725
Publisher
Journal
Research Unit
PubMed ID
PubMed Central ID
Embedded videos
Additional Links
Type
Journal article
Language
en
Description
© 2022 The Authors. Published by Taylor & Francis. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.1080/16078454.2022.2082725
Series/Report no.
ISSN
1024-5332